Prognostic Markers in Follicular Lymphoma
Author Information
Author(s): F. Pezzella, M. Jones, E. Ralfkiaer, J. Ersbo, K.C. Gatter, D.Y. Mason
Primary Institution: John Radcliffe Hospital, Oxford
Hypothesis
Does the presence of bcl-2 protein expression and 14;18 translocation serve as useful prognostic markers in follicular lymphoma?
Conclusion
The study found that neither the 14;18 translocation nor bcl-2 protein expression are useful prognostic markers in clinical practice for follicular lymphoma.
Supporting Evidence
- The study included long-term follow-up data of up to 17 years.
- Previous studies had conflicting results regarding the prognostic significance of the 14;18 translocation.
- Statistical analysis showed no significant differences in survival based on bcl-2 expression or gene rearrangement.
Takeaway
This study looked at 70 patients with a type of cancer called follicular lymphoma and found that certain genetic changes didn't help predict how well patients would do.
Methodology
The study analyzed tissue samples from 70 cases of follicular lymphoma for bcl-2 protein expression and 14;18 translocation, with long-term follow-up data.
Potential Biases
The study may have bias due to the varying treatments received by patients from different centers.
Limitations
The study's findings may be affected by the heterogeneity of treatment received by patients from different centers over a long period.
Participant Demographics
The study included 70 patients, with 35 men and 35 women, diagnosed with follicular lymphoma.
Statistical Information
Confidence Interval
95% CI from 0.4 to 2.61 for bcl-2 protein expression; 95% CI from 0.83 to 6.81 for bcl-2 gene rearrangement.
Want to read the original?
Access the complete publication on the publisher's website